Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Sunday. The firm issued a hold rating on the medical research company’s stock.

Other research analysts have also issued research reports about the company. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research note on Friday, January 3rd. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Cytosorbents has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $1.01 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a market cap of $55.23 million, a PE ratio of -2.81 and a beta of 0.58. The firm has a 50 day simple moving average of $0.92 and a 200-day simple moving average of $1.02. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.59.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTSO. Sargent Investment Group LLC raised its holdings in shares of Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after purchasing an additional 192,747 shares during the period. Atomi Financial Group Inc. acquired a new stake in Cytosorbents during the 3rd quarter worth approximately $51,000. Finally, Geode Capital Management LLC raised its holdings in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.